Do analysts rate INCR or DARE?

Dare Bioscience has a consensus target price of $6.50, suggesting a potential upside of 764.36%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger earnings & valuation, INCR or DARE?

InterCure has higher revenue and earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InterCure $78.47M 0.73 -$10.37M $0.15 35.07 Dare Bioscience $1.03M 14.36 -$13.40M -$0.70 N/A

Which has preferable earnings & valuation, DARE or CLNN?

Dare Bioscience has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dare Bioscience $1.03M 14.36 -$13.40M -$0.70 N/A Clene $197K 276.37 -$26.17M -$3.50 N/A

Is DARE or CLNN more profitable?

Dare Bioscience has a net margin of -803.80% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience -803.80% -748.30% -38.75% Clene -20,063.96% N/A -137.04%

Do analysts recommend RYM or DARE?

Dare Bioscience has a consensus price target of $6.50, suggesting a potential upside of 764.36%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is RYM or DARE more profitable?

RYTHM has a net margin of -6.20% compared to Dare Bioscience's net margin of -803.80%. RYTHM's return on equity of -12.57% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets RYTHM -6.20% -12.57% -2.60% Dare Bioscience -803.80% -748.30% -38.75%

Do analysts rate DARE or AGFY?

Dare Bioscience presently has a consensus target price of $6.50, indicating a potential upside of 764.36%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Dare Bioscience is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is DARE or AGFY more profitable?

Agrify has a net margin of -424.11% compared to Dare Bioscience's net margin of -803.80%. Agrify's return on equity of -185.90% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience -803.80% -748.30% -38.75% Agrify -424.11% -185.90% -72.67%

Dare Bioscience (DARE) Competitors

$0.75 -0.06 (-6.86%)

As of 10:53 AM Eastern

Compare

DARE vs. INCR, CLNN, RYM, GRCE, and AGFY

Should you buy Dare Bioscience stock or one of its competitors? Dare Bioscience's main competitors and comparable companies include InterCure (INCR), Clene (CLNN), RYTHM (RYM), Grace Therapeutics (GRCE), and Agrify (AGFY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dare Bioscience compare to InterCure?

InterCure (NASDAQ:INCR) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

InterCure has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

In the previous week, InterCure's average media sentiment score of 0.00 equaled Dare Bioscience'saverage media sentiment score.

Company	Overall Sentiment
InterCure	Neutral
Dare Bioscience	Neutral

InterCure has higher revenue and earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.73	-$10.37M	$0.15	35.07
Dare Bioscience	$1.03M	14.36	-$13.40M	-$0.70	N/A

InterCure has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. InterCure's return on equity of 0.00% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Dare Bioscience	-803.80%	-748.30%	-38.75%

8.3% of InterCure shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 4.1% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dare Bioscience has a consensus target price of $6.50, suggesting a potential upside of 764.36%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

InterCure beats Dare Bioscience on 9 of the 14 factors compared between the two stocks.

How does Dare Bioscience compare to Clene?

Dare Bioscience (NASDAQ:DARE) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

In the previous week, Clene had 3 more articles in the media than Dare Bioscience. MarketBeat recorded 3 mentions for Clene and 0 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.00 beat Clene's score of -0.24 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Dare Bioscience	Neutral
Clene	Neutral

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dare Bioscience has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Clene has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Dare Bioscience has a net margin of -803.80% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
Clene	-20,063.96%	N/A	-137.04%

Dare Bioscience currently has a consensus price target of $6.50, indicating a potential upside of 764.36%. Clene has a consensus price target of $34.00, indicating a potential upside of 711.46%. Given Dare Bioscience's higher possible upside, equities analysts plainly believe Dare Bioscience is more favorable than Clene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Dare Bioscience has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	14.36	-$13.40M	-$0.70	N/A
Clene	$197K	276.37	-$26.17M	-$3.50	N/A

Summary

Dare Bioscience beats Clene on 9 of the 16 factors compared between the two stocks.

How does Dare Bioscience compare to RYTHM?

RYTHM (NASDAQ:RYM) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

RYTHM has a beta of 9.44, suggesting that its share price is 844% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

In the previous week, RYTHM had 4 more articles in the media than Dare Bioscience. MarketBeat recorded 4 mentions for RYTHM and 0 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.00 beat RYTHM's score of -0.24 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
RYTHM	Neutral
Dare Bioscience	Neutral

6.0% of RYTHM shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dare Bioscience has a consensus price target of $6.50, suggesting a potential upside of 764.36%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dare Bioscience has lower revenue, but higher earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$51.01M	0.95	-$33.26M	-$10.53	N/A
Dare Bioscience	$1.03M	14.36	-$13.40M	-$0.70	N/A

RYTHM has a net margin of -6.20% compared to Dare Bioscience's net margin of -803.80%. RYTHM's return on equity of -12.57% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Dare Bioscience	-803.80%	-748.30%	-38.75%

Summary

Dare Bioscience beats RYTHM on 10 of the 16 factors compared between the two stocks.

How does Dare Bioscience compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Grace Therapeutics has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Grace Therapeutics' return on equity of -36.11% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Dare Bioscience	-803.80%	-748.30%	-38.75%

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by company insiders. Comparatively, 4.1% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Grace Therapeutics has higher earnings, but lower revenue than Dare Bioscience. Grace Therapeutics is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Dare Bioscience	$1.03M	14.36	-$13.40M	-$0.70	N/A

In the previous week, Grace Therapeutics had 2 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for Grace Therapeutics and 0 mentions for Dare Bioscience. Grace Therapeutics' average media sentiment score of 1.03 beat Dare Bioscience's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Grace Therapeutics	Positive
Dare Bioscience	Neutral

Grace Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 179.72%. Dare Bioscience has a consensus target price of $6.50, indicating a potential upside of 764.36%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Grace Therapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Summary

Dare Bioscience beats Grace Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Agrify?

Dare Bioscience (NASDAQ:DARE) and Agrify (NASDAQ:AGFY) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Dare Bioscience presently has a consensus target price of $6.50, indicating a potential upside of 764.36%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Dare Bioscience is more favorable than Agrify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Agrify has a net margin of -424.11% compared to Dare Bioscience's net margin of -803.80%. Agrify's return on equity of -185.90% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
Agrify	-424.11%	-185.90%	-72.67%

Dare Bioscience has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Agrify has a beta of 9.96, suggesting that its share price is 896% more volatile than the broader market.

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 6.0% of Agrify shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by insiders. Comparatively, 2.2% of Agrify shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dare Bioscience has higher earnings, but lower revenue than Agrify. Dare Bioscience is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	14.36	-$13.40M	-$0.70	N/A
Agrify	$12.26M	3.76	-$41.75M	-$22.65	N/A

In the previous week, Agrify had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 1 mentions for Agrify and 0 mentions for Dare Bioscience. Agrify's average media sentiment score of 0.67 beat Dare Bioscience's score of 0.00 indicating that Agrify is being referred to more favorably in the news media.

Company	Overall Sentiment
Dare Bioscience	Neutral
Agrify	Positive

Summary

Dare Bioscience beats Agrify on 9 of the 16 factors compared between the two stocks.

Get Dare Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DARE vs. The Competition

Export

Metric	Dare Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.81M	$12.62B	$7.28B	$13.01B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-1.08	797.33	274.92	25.63
Price / Sales	14.36	852.31	673.28	90.00
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	3.76	10.60	10.34	6.27
Net Income	-$13.40M	$2.84B	$3.49B	$360.12M
7 Day Performance	0.56%	-0.78%	-1.13%	-0.31%
1 Month Performance	-6.18%	-1.63%	-3.55%	-3.67%
1 Year Performance	-64.86%	2.51%	14.81%	5.14%

Dare Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DARE Dare Bioscience	2.4216 of 5 stars	$0.75 -6.9%	$6.50 +764.4%	-60.8%	$14.81M	$1.03M	N/A	24
INCR InterCure	1.1992 of 5 stars	$5.13 -3.0%	N/A	-24.6%	$56.12M	$78.47M	34.20	350
CLNN Clene	1.9096 of 5 stars	$4.02 +22.6%	$34.00 +745.8%	-29.9%	$51.65M	$197K	N/A	100	High Trading Volume
RYM RYTHM	0.6295 of 5 stars	$21.65 -1.5%	N/A	-39.2%	$47.16M	$51.01M	N/A	140	News Coverage
GRCE Grace Therapeutics	2.0437 of 5 stars	$2.23 -2.6%	$6.00 +169.1%	-31.8%	$46.91M	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DARE) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dare Bioscience (DARE) Competitors

DARE vs. INCR, CLNN, RYM, GRCE, and AGFY

How does Dare Bioscience compare to InterCure?

Summary

How does Dare Bioscience compare to Clene?

Summary

How does Dare Bioscience compare to RYTHM?

Summary

How does Dare Bioscience compare to Grace Therapeutics?

Summary

How does Dare Bioscience compare to Agrify?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dare Bioscience (DARE) Competitors

DARE vs. INCR, CLNN, RYM, GRCE, and AGFY

How does Dare Bioscience compare to InterCure?

Which has more risk & volatility, INCR or DARE?

Does the media prefer INCR or DARE?

Which has stronger earnings & valuation, INCR or DARE?

Is INCR or DARE more profitable?

Do institutionals and insiders have more ownership in INCR or DARE?

Do analysts rate INCR or DARE?

Summary

How does Dare Bioscience compare to Clene?

Does the media refer more to DARE or CLNN?

Do insiders and institutionals have more ownership in DARE or CLNN?

Which has more volatility & risk, DARE or CLNN?

Is DARE or CLNN more profitable?

Do analysts recommend DARE or CLNN?

Which has preferable earnings & valuation, DARE or CLNN?

Summary

How does Dare Bioscience compare to RYTHM?

Which has more risk and volatility, RYM or DARE?

Does the media prefer RYM or DARE?

Do insiders & institutionals hold more shares of RYM or DARE?

Do analysts recommend RYM or DARE?

Which has preferable earnings and valuation, RYM or DARE?

Is RYM or DARE more profitable?

Summary

How does Dare Bioscience compare to Grace Therapeutics?

Is GRCE or DARE more profitable?

Do insiders & institutionals have more ownership in GRCE or DARE?

Which has better valuation & earnings, GRCE or DARE?

Does the media prefer GRCE or DARE?

Do analysts rate GRCE or DARE?

Which has more risk & volatility, GRCE or DARE?

Summary

How does Dare Bioscience compare to Agrify?

Do analysts rate DARE or AGFY?

Is DARE or AGFY more profitable?

Which has more volatility and risk, DARE or AGFY?

Do insiders & institutionals believe in DARE or AGFY?

Which has better valuation and earnings, DARE or AGFY?

Does the media refer more to DARE or AGFY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools